Hagens Berman Sobol Shapiro LLP, alongside eight other law firms, has requested $20 million in fees and expenses from a Massachusetts federal court after securing a $58 million settlement with Shire PLC in an antitrust class action. The lawsuit, filed in 2016, accused Shire and co-defendant Actavis of engaging in an anticompetitive scheme to delay the release of a generic version of the ADHD drug Intuniv.
Hagens Berman $20M Antitrust Suit : Settlement Overview
The settlement follows years of complex litigation, with claims that Shire and Actavis struck a “reverse payment agreement” to delay competition in the Intuniv market. The attorneys representing the class of direct purchasers are asking for one-third of the settlement amount—just over $19 million—in addition to approximately $800,000 in litigation costs.
Case Background
The lawsuit alleged that Shire and Actavis agreed to delay the generic Intuniv until December 2014, in exchange for Shire holding back its own authorized generic during Actavis’ 180-day exclusivity period. The direct purchasers claimed that this arrangement stifled competition and kept drug prices artificially high.
